Fintel reports that on August 1, 2025, HC Wainwright & Co. downgraded their outlook for Zynex (NasdaqGS:ZYXI) from Buy to ...

Zynex Inc (NASDAQ:ZYXI) is set to release its Q2 2025 earnings on Jul 31, 2025. The consensus estimate for Q2 2025 revenue is $27.38 million, and the earnings are expected to come in at -$0.20 per ...

Zynex (ZYXI) delivered earnings and revenue surprises of -60.00% and -17.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Q2 2025 Earnings Call Transcript July 31, 2025 Zynex, Inc. misses on earnings expectations. Reported EPS is $-0.66 EPS, expectations were $-0.13. Operator: Good afternoon, ladies and gentlemen, and ...

An announcement from Zynex ( (ZYXI) ) is now available.

Zynex (ZYXI) has appointed Steven Dyson as chief executive officer. His employment will begin on August 18, 2025. ZYXI is +2.35% to $2.61. Source: Press Release ...

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of ...

Zynex (NASDAQ:ZYXI), a medical technology company specializing in non-opioid pain management devices, issued its second quarter 2025 results on July 31, 2025. The release highligh ...

Find the latest Zynex, Inc. (ZYXI) stock quote, history, news and other vital information to help you with your stock trading and investing.

Zynex, Inc. reports Q2 2025 earnings with a $40M cost-reduction plan, leadership transitions, and FDA progress on its NiCO pulse oximeter.